Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Xeris Q2 '18 10-Q Filing Highlights

Here is a brief preview of this blast: Xeris Pharmaceuticals filed its first 10-Q statement since its IPO in June 2018. In the 10-Q, Xeris confirmed filing of its Glucagon Rescue Pen in Q3 ‘18 via the 505(b)(2) pathway. Yesterday, Xeris released its Q2 ’18 earnings but did not have an associated earnings webcast.